CD4 and lymphoma: Remarkably, most of the AITL patients carrying the RHOAG17V mutation also have TET2 mutations45,46 indicating a cooperation between these two mutations in disrupting normal CD4 T-cell phenotype and function in this aggressive lymphoma.